APPLIED DNA SCIENCES INC. news, videos and press releases
For more news please use our advanced search feature.
APPLIED DNA SCIENCES INC. - More news...
APPLIED DNA SCIENCES INC. - More news...
- Applied DNA Reports First Quarter Fiscal 2025 Financial Results and Highlights Operational Progress
- Applied DNA to Report First Quarter Fiscal 2025 Financial Results After Market Close on Thursday, February 13, 2025
- Applied DNA Reminds Shareholders to Vote Ahead of Special Meeting on February 14
- Applied DNA Completes Buildout of GMP Facility for LineaDNA IVT Templates
- Applied DNA Reschedules Investor Update Call in Observance of the National Day of Mourning in Recognition of the Passing of Former President Jimmy Carter
- Applied DNA Customer ÚHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-Cell Therapy Produced from Linea DNA
- Applied DNA Announces Fourth Quarter and Fiscal Year 2024 Financial Results, Announces Strategic Restructuring to Prioritize the Manufacture of Critical Starting Materials for Genetic Medicines
- Applied DNA to Report Fourth Quarter and Fiscal Year 2024 Financial Results After Market Close on December 17, 2024; Sets Webcast and Conference Call for January 9, 2025, to Coincide with Update on GMP Manufacturing Facility Build-out
- Applied DNA Announces Pricing of $6.5 Million Registered Direct Offering and Concurrent Private Placement
- Applied DNA to Participate in the 2024 Maxim Healthcare Virtual Summit on Wednesday, October 16
- Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement
- Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 3rd Annual mRNA Process Development & Manufacturing Summit
- Applied DNA Receives Linea DNA Follow-on Order from Global Manufacturer of IVDs for Cancer Diagnostic Application
- Applied DNA Launches Mpox Clade I and Clade II Testing Service
- Applied DNA Selected by LRQA for Isotopic Testing Pilot Project in Pakistan
- Applied DNA Submits Validation Package to New York State Department of Health to Expand Linea Mpox Virus 1.0 Assay to Mpox Clade I
- Applied DNA To Submit Application to New York State Department of Health to Expand Intended Use of Linea Mpox Virus 1.0 Assay to Mpox Clade I
- Applied DNA Announces Third Quarter Fiscal Year 2024 Financial Results
- Applied DNA to Report Third Quarter Fiscal 2024 Financial Results on Thursday, August 8, 2024
- CORRECTING AND REPLACING: Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 4th Annual mRNA-based Therapeutics Summit
- Applied DNA to Showcase Linea IVT as a High-yield, dsRNA-Mitigated Platform for the GMP Manufacture of RNA at the 4th Presentation Annual mRNA-based Therapeutics Summit
- Applied DNA Enters into Multi-Year Commercialization Agreement with Indus Group for Large-Scale Implementation of CertainT Cotton Traceability
- U.S. Defense Logistics Agency Exercises 1-Year Option Period in Applied DNA Counterfeit Mitigation Contract
- Applied DNA and Alphazyme Conclude Linea(TM) RNAP Manufacturing Scale-up Project, Deliver Substantial Improvement in Linea(TM) IVT Platform Economics
- Applied DNA Partners with GenXys Health Care Systems to Deploy Clinical Decision Support System for Pharmacogenetic (PGx) Testing
- Applied DNA Receives Approval for TR8(TM) Pharmacogenomic (PGx) Testing Service from New York State Department of Health
- Applied DNA Announces Notice of Allowance for U.S. Patent Covering Fundamental Aspect of its Linea(TM) IVT Platform
- Applied DNA Announces Pricing of $12 Million Public Offering
- Institute of Hematology and Blood Transfusion (Prague) to Present on Successful Use of Applied DNA's Linea DNATM for the Non-Viral Manufacture of CAR T-Cell Therapy for Refractory AML
- Applied DNA Announces Second Quarter Fiscal Year 2024 Financial Results
